

Neuren's NNZ-2566 Programme selected as one of the Top 10 Neurosciences Projects by Windhover Conferences/Elsevier Business Intelligence

SYDNEY, Australia, 19 October 2012: Neuren Pharmaceuticals Limited (ASX:NEU) has been selected as one of the Top 10 Neurosciences Projects to Watch by Windhover Conferences, a division of Elsevier Business Intelligence. Every year, the Windhover Therapeutic Area Partnerships (TAP) expert panel selects the top 10 projects chosen to present in a major therapeutic area based on the likelihood of their success as future products. The neurosciences expert panel was headed by Dr Harry Tracy, President of NI Research. Neuren was also chosen as a TAP Top 10 project in 2008. Larry Glass, Neuren's CEO, will present the NNZ-2566 programme at the Therapeutic Area Partnerships conference in Boston, Massachusetts (28-30 November 2012).

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive neuroscience opportunities the industry has to offer," said David Cassak, Vice President, Content, Windhover Conferences, a division of Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."

Commenting on the selection, Larry Glass said, "We are very pleased to have been chosen as one of the top 10 neurosciences projects. Over the past few years, with development of the oral formulation, the potential uses of NNZ-2566 have expanded well beyond its initial therapeutic target in TBI to include a wider range of conditions that we believe represent extremely important areas of unmet medical need as well as significant opportunities for partnerships and commercialization. That our view is shared by independent experts in our field is most gratifying."

About NNZ-2566

NNZ-2566 is a synthetic analogue of a naturally occurring neuroprotective and neurotrophic molecule derived from IGF-1, a growth factor produced by brain cells as well as in other parts of the body. The intravenous form of NNZ-2566 is presently in a Phase II clinical trial in patients with moderate to severe traumatic brain injury which has received Fast Track designation from the US FDA. The company is currently undertaking final preparations to initiate two additional Phase II trials with the oral form of NNZ-2566 – one in patients with concussion or mild TBI and one in patients with Rett Syndrome.

About Neuren

Neuren Pharmaceuticals is a biopharmaceutical company developing new therapies for brain injury, neurodevelopmental and neurodegenerative disorders and cancer. Neuren presently has two clinical-stage molecules, NNZ-2566 and Motiva®, in Phase 2 clinical trials largely funded by the US Army and the National Health and Medical Research Council, respectively. Through its subsidiary, Perseis Therapeutics Limited, Neuren is developing monoclonal antibodies against Trefoil Factors 1 and 3, proteins produced by cancer cells that are associated with cancer spread and reduced patient survival.

For more information, please contact:

Larry Glass, Neuren CEO

lglass@neurenpharma.com

Tel: +1 301 941 1830